Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Rituximab and Combination Chemotherapy in Treating Patients With Primary Central Nervous System Lymphoma

This study has suspended participant recruitment.
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)
ClinicalTrials.gov Identifier:
NCT00335140
First received: June 7, 2006
Last updated: July 11, 2012
Last verified: February 2010
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has suspended participant recruitment.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)